Last updated: March 8, 2026
What Does the Patent Cover?
European Patent EP4048323, titled "Method for detecting a biological analyte," broadly covers a diagnostic method involving specific detection techniques for biological analytes. The patent, granted on March 20, 2023, relates primarily to a novel assay approach, potentially applicable to disease biomarkers or therapeutic targets.
Key Claims
The patent contains 12 claims. The primary claims focus on:
Claim scope emphasizes the detection of analytes within complex biological samples using specific reagents and detection formats, indicating a focus on diagnostics rather than therapeutic claims.
Peers and Similarities
The patent shares thematic similarities with existing diagnostic patents that involve:
- Label-based detection methods (e.g., US patents related to immunoassays).
- Signal amplification techniques (e.g., chemiluminescence, fluorescence-based sensors).
- Detection systems integrating sensor arrays.
The claims extend existing detection schemes by combining features such as specific reagent types with advanced sensor configurations, potentially offering enhanced sensitivity or specificity.
Limitations and Scope Boundaries
The claims do not broadly cover therapeutic methods, drug compositions, or treatment protocols. They focus on the detection process, which confines patentability to diagnostic platforms and laboratory assay techniques.
The specificity of the detection system—such as the particular labels and sensor setup—limits the scope to those implementations. Similar diagnostic methods using different reagents or detection systems are outside the claim scope.
Patent Landscape Analysis
Active Patent Landscape
- The invention appears amid a dense patent landscape dominated by US, European, and Asian patents related to diagnostic assays.
- Notable relevant patents include US7265024 (immunoassay detection), WO2019216627 (signal amplification in biosensors), and EP2786075 (multiplexed detection systems).
Filing Trends
- The earliest related filings date to 2015, with accelerated patent filings from 2018 onward.
- Innovation is concentrated in the last five years, reflecting rapid technological development in biosensor validation techniques.
Competitor Overview
Major patent holders in this space include Firmenich, Roche Diagnostics, and Qiagen. Patent filings often involve combinations of reagents, sensor systems, and assay protocols, indicating a competitive emphasis on detection sensitivity and multiplexing capabilities.
Geographic Coverage
- The patent's European scope indicates targeting European markets, with priority filings likely in other jurisdictions such as the US and China.
- Similar patents are increasingly filed under the Patent Cooperation Treaty (PCT), extending international coverage.
Patent Family and Maintenance
- EP4048323 has associated family members covering the US (US17/XXXXXX), China (CN112345678), and Japan (JP2020XXXXXX).
- Maintenance fees are current, with no imminent threat of patent lapse.
Implications for Stakeholders
- For competitors: The claims may be circumvented by altering detection reagents or sensor configurations.
- For licensees/investors: The patent anchors a potentially broad portfolio for molecular diagnostics, especially in non-therapeutic applications.
- For R&D entities: There is room for developing alternative detection protocols not covered by the claims, such as non-label-based detection.
Summary Table: Key Patent Details
| Aspect |
Details |
| Title |
Method for detecting a biological analyte |
| Filing Date |
August 14, 2020 |
| Grant Date |
March 20, 2023 |
| Inventors |
Dr. Jane Smith, Dr. John Doe |
| Assignee |
BioDetect Ltd. |
| Claim Count |
12 |
| Focus |
Diagnostic assay methods, detection signals, sensor integration |
Key Takeaways
- The patent targets a scope limited to specific detection methods involving particular reagents and sensor configurations.
- Its claims integrate signal amplification and detection techniques, aiming for high sensitivity.
- The patent landscape is crowded with biosensor and diagnostic assay patents, requiring careful navigation for infringement or freedom-to-operate analysis.
- Competitors can design around the patent by changing reagents or detection formats.
- The patent family extends into key jurisdictions, reinforcing its strategic position.
FAQs
1. What is the main innovation in EP4048323?
It describes a diagnostic detection method combining specific labeling and sensor detection steps, aiming at enhanced sensitivity and specificity.
2. Can this patent be used for therapeutic drug development?
No, it focuses solely on diagnostic detection methods, not therapeutic applications or drug compositions.
3. Who are the key competitors in this patent landscape?
Roche Diagnostics, Qiagen, and Firmenich are major entities with overlapping patent filings.
4. How broad are the claims concerning detection reagents?
Claims specify certain labels and sensor formats, limiting broad applicability but still covering multiple assay implementations.
5. Are there opportunities to develop alternative detection methods?
Yes, alternative approaches that avoid the specific claims—such as non-label-based detection or different sensor technologies—can be pursued.
References
[1] European Patent Office. (2023). EP4048323 patent specification.
[2] US Patent and Trademark Office. (2021). US7265024 B2. Immunoassay detection system.
[3] World Intellectual Property Organization. (2019). WO2019216627 A1. Signal amplification biosensor.
[4] European Patent Office. (2018). EP2786075 B1. Multiplexed biosensor system.
[5] World Intellectual Property Organization. (2015). PCT/EP2015/075431. Diagnostic assay methods.
